免疫检查点抑制剂诱导白癜风的发生与结局:回顾性队列研究
基于法国药物警戒数据库的回顾性研究,分析ICI治疗相关白癜风病例。在95例患者中,帕博利珠单抗、纳武利尤单抗和伊匹木单抗诱导白癜风的中位发生时间分别为5.4、5.0和3.8个月。37例(45%)因疾病进展停用ICI,所有患者中位随访33个月。
要点
- ICI诱导白癜风多见于黑色素瘤患者,中位发生时间因药物而异。
- 多数患者伴其他免疫相关不良反应,如结肠炎、甲状腺炎等。
- 帕博利珠单抗或纳武利尤单抗诱导白癜风消退可能提示疾病进展。
核心结论
- ICI诱导的白癜风在真实世界中多发生于黑色素瘤患者,且常伴随其他免疫相关不良反应。
- 帕博利珠单抗或纳武利尤单抗诱导的白癜风消退可能是疾病进展的标志。
研究设计与样本
- 回顾性研究,使用法国药物警戒数据库(FPD),纳入从ICI在法国上市至2019年1月1日的白癜风病例。
- 共识别95例ICI治疗相关白癜风患者。
主要发现
- 帕博利珠单抗、纳武利尤单抗和伊匹木单抗诱导白癜风的中位发生时间分别为5.4、5.0和3.8个月。
- 37例患者(45%)因疾病进展停用ICI治疗。
- 所有患者中位随访时间为33个月(四分位距2-56)。
- 多数患者出现其他相关药物不良反应,如结肠炎、瘙痒、甲状腺功能减退、甲状腺功能亢进、甲状腺炎、胰腺炎和胃炎。
临床怎么用
- 临床应监测ICI治疗患者白癜风的发生,并警惕其可能伴随的其他免疫相关不良反应。
- 白癜风消退(尤其帕博利珠单抗或纳武利尤单抗相关)需评估疾病进展可能。
局限性
- 基于药物警戒数据库的回顾性研究,可能存在报告偏倚和混杂因素。
- 样本量有限,需未来研究评估白癜风结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of immune checkpoint inhibitors (ICI) in melanoma and non-small cell lung cancer patients is associated with the onset of vitiligo. However, previous studies have suggested conflicting results on the conditions of occurrence of ICI-induced vitiligo. OBJECTIVE: The aim of this study was to describe the occurrences and outcomes of several cases of ICI-induced vitiligo. METHODS: A retrospective study was carried out using the French Pharmacovigilance Database (FPD) between the beginning of the commercialization of ICI in France and 1 January 2019, selecting for analysis the vitiligo reactions of patients due to treatment with ICI. RESULTS: Among the 95 case patients identified in the FPD, the median times to onset of vitiligo after the start of pembrolizumab, nivolumab and ipilimumab therapies were 5.4, 5.0, and 3.8 months, respectively. Furthermore, 37 patients (45%) discontinued ICI treatment due to disease progression. The median follow-up time of all patients was 33 months (interquartile range 2-56). CONCLUSIONS: This study provided an overall picture of ICI-induced vitiligo in daily medical practice on a large number of pharmacovigilance observations of case patients. Among the observations of ICI-induced vitiligo, the diagnosed cancer was melanoma for almost all patients. Most patients in the study experienced other associated adverse drug reactions (ADRs), such as colitis, pruritus, hypothyroidism, hyperthyroidism, thyroiditis, pancreatitis, and gastritis. Furthermore, our data suggest that the resolution of pembrolizumab- or nivolumab-induced vitiligo could be a marker of disease progression. Future studies evaluating vitiligo outcomes are warranted.
引用
- Babai S, Voisin AL, Bertin C, et al. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study. Drug Saf. 2020. PMID: 31630381. doi:10.1007/s40264-019-00875-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。